KEY DETAILS
Novo Nordisk's investor day left Wall Street unconvinced, reinforcing Eli Lilly's growing dominance in the GLP-1 market.
Reports of lawsuits against GLP-1 manufacturers over vision loss claims signal growing legal scrutiny that patients should be aware of.
Ozari Health's recognition as a top source for compounded tirzepatide highlights another option some patients consider for access.
Multiple GLP-1 drug makers now face lawsuits alleging their medications carry undisclosed risks of sudden vision loss.
Ongoing questions about whether GLP-1 drugs may raise the risk of sudden blindness are prompting closer research and patient concern.
Novo Nordisk held its investor day today, and the market's response made clear that Wall Street wanted more than what the company delivered. Shares reacted poorly, and the broader takeaway was that Eli Lilly's lead in the GLP-1 market keeps widening. On the legal side, several drug makers now face lawsuits alleging their medications carry undisclosed risks of sudden vision loss, a concern that touches patients regardless of which brand they use. And for those weighing access options outside traditional pharmacies, one compounding pharmacy picked up a notable industry recognition.
The disappointment following Novo Nordisk's investor day was not about a single missed number. Investors had been looking for a clearer answer to Eli Lilly's continued gains in the GLP-1 market, and the presentation did not give them one. Novo's stock reaction reflected a broader sense that the company's competitive position has slipped, and that gap appears to be widening rather than closing. For patients and prescribers watching the field, the practical effect may become clearer later, in pricing, supply, or which drug gets pushed harder by manufacturers competing for share.
That competitive pressure sits alongside a separate story that has nothing to do with market share and everything to do with patient safety. Reports emerged today of lawsuits filed against GLP-1 manufacturers over claims of vision loss linked to their drugs. The suits point to a pattern of legal scrutiny that is likely to grow as more patients and attorneys review adverse event reports. Patients currently taking these medications may want to pay attention to how these cases develop, even before any court reaches a decision, simply because they speak to what companies did or did not disclose about risk.
Legal exposure over branded drugs is part of why some patients look beyond traditional prescriptions in the first place, and compounded tirzepatide remains one of the more common alternatives. Ozari Health was named a top source for compounded tirzepatide for 2026, a recognition that will likely draw more attention to the company among patients comparing options. Compounded versions can offer a different price point and availability than brand-name drugs, though patients should understand that compounded medications are not identical to FDA-approved products. Anyone considering this route should talk with a prescriber about what compounding means for quality control and oversight before making a decision.
The lawsuits are not limited to one company. Multiple GLP-1 drug makers now face legal claims that their medications carry risks of sudden vision loss that were not adequately disclosed to patients or doctors. This detail matters because it suggests the concern is not tied to one drug's formulation but potentially to the class of medications as a whole. Manufacturers named in these suits will likely respond in the coming weeks, and how they address the disclosure question could shape both the litigation and how doctors discuss risk with patients going forward.
Behind these lawsuits is an open question in the research community: whether GLP-1 drugs may raise the risk of sudden blindness in some patients. Researchers are looking more closely at this possible connection, and the answer is not yet settled. Patients who notice any changes in vision while taking these medications should mention it to their doctor promptly, regardless of what the ongoing research eventually concludes. The uncertainty itself is part of why the lawsuits are gaining attention, since patients and their doctors want clarity on a risk that current labels may not fully capture.
Two things are worth acting on now. If you take a GLP-1 medication, it is reasonable to track any changes in vision and raise them with your doctor without delay, given the lawsuits and the open research questions. If you are considering compounded options like the ones Ozari Health offers, ask direct questions about sourcing and oversight so you understand exactly what you are taking. The competitive pressure between Novo Nordisk and Eli Lilly will keep playing out in the market, but the vision-related questions are the ones that most directly affect patient decisions right now.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.